Business Development Executive
Parman Tech is looking for an entrepreneurial-minded person with a technical background, but primary
experience in business development activities in life science instrumentation, medical device, or
pharmaceutical companies. This person is expected to develop a strong relationship with the existing
team while working initially as a part-time consultant. During this period, the ideal person will 1)
identify and establish relationships with a few Strategic Partners, i.e., companies that could enable us to
develop our technology more quickly or expand our market, 2) conduct market research in gene therapy
and nanomedicine that will strengthen our business case for investment from funding agencies and
private investors, 3) help write parts of SBIR proposals, e.g., Commercialization Plan and Market Analysis
sections. Following the acquisition of the next level of funding, depending on mutual interest, we
expect to welcome this person onboard as a first full-time Parman Tech employee with commensurate
opportunities for seniority and equity in the company. Principal tasks for a full-time employee will be to
lead efforts in fundraising, partnerships, and all business development and customer-facing activities.
This role is for someone who wants to provide significant contributions to the strategic and tactical
directions of a budding company. He/she must be able to tolerate the uncertainty and limited
immediate compensation inherent in an entrepreneurial venture for the opportunity to contribute in a
very meaningful way to its development and to participate in the very significant upside of the venture.
About Parman Tech
Parman Tech is an early-stage life science instrumentation start-up located in the I-270 Biotech corridor
of Maryland. The company is developing a new analytical instrument for separation of nanoparticles,
which it will initially market to companies and institutions working in gene therapy and nanomedicine.
The novel concept, based on technology created at the National Institute of Standards and Technology
(NIST) by the company’s founder, enables continuous separation of nanoparticles based on size or
density. This will allow those working in gene therapy and nanomedicine to both analyze and purify
therapies based on degree of functionalization or on exosome fill fraction. The ultimate impact will be
improved therapies at lower costs for millions of patients. The company’s work during the National
Science Foundation (NSF) I-Corps program identified a significant need for the capability it can provide
to its target markets and revealed that there are several additional markets for this technology
throughout the pharmaceutical industry and beyond.
Parman Tech, founded at the end of 2018, consists of a two-person team that has successfully acquired
more than half a million dollars in state and federal grants with which it has established a substantial
R&D foundation. We are now looking to accelerate our efforts by expanding our team and seeking
larger sources of funding. Our immediate funding goals are SBIR grant from both the National Science
Foundation and the National Institutes of Health.
For information, contact Contact: John J Curry, email@example.com